We are overjoyed to congratulate Scott Plotkin, MD, PhD, CTF Clinical Care Advisor Board Chair and also the recent Von Recklinghausen awardee, on his well-deserved promotion to Executive Director of the Stephen E. and Catherine Pappas Center for Neuro-Oncology at Massachusetts General Hospital (MGH) Cancer Center and Chief of the Division of Neuro-Oncology in the Department of Neurology.
Dr. Plotkin is an international leader in Neuro-oncology and Neurofibromatosis, an NIH- and DoD-funded researcher, skilled clinician, and dedicated educator. His leadership and skills will lead the neuro-oncology program in to a new generation of scientific and clinical advancement, excellence, and continued growth.
After receiving his AB from Harvard University, Dr. Plotkin earned both an MD and PhD from Tulane University, where he completed his internship. Following his return to Boston to complete his residency, Dr. Plotkin became chief resident in neurology for the combined Massachusetts General/Brigham and Women’s Hospital program.
Dr. Plotkin was a neuro-oncology fellow at Mass General and then joined the MGH faculty in 2003. In 2005, he was appointed director of the neurofibromatosis clinic. Since then, Dr. Plotkin has provided leadership within the Mass General Cancer Center as associate director at the Pappas Center for Neuro-Oncology, director for Cancer Neurology, and, since 2018, Interim Executive Director of the Pappas Center. Academically, he is Professor of Neurology at Harvard Medical School and serves as Chair of the AAN Section on Neuro-Oncology. He has been instrumental in developing the national match for fellowship training, and has trained a generation of researchers and clinicians in the field of neuro-oncology.
On his new role and vision for neuro-oncology, Dr. Plotkin says, “I am honored to build on the strengths and track record of our incredibly talented and caring team at the Pappas Center – while bringing a new vision and focus on innovation and excellence in a number of areas, including immunotherapy, targeted therapy, neurotoxicity, and palliative care.”
